{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:37:41Z","timestamp":1791250661251,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Ministry of Science","award":["RTA 2005-00017"],"award-info":[{"award-number":["RTA 2005-00017"]}]},{"name":"Spanish Ministry of Science","award":["AGL2008-03710"],"award-info":[{"award-number":["AGL2008-03710"]}]},{"name":"EU Network of Excellence EPIZONE"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.vaccine.2010.02.018","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T10:27:47Z","timestamp":1267180067000},"page":"2937-2944","source":"Crossref","is-referenced-by-count":73,"title":["Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR\u2212\/\u2212 mice induced by different DNA vaccination regimens"],"prefix":"10.1016","volume":"28","author":[{"given":"Gema","family":"Lorenzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mart\u00edn-Folgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Hevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Boshra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"August (2)","key":"10.1016\/j.vaccine.2010.02.018_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.20506\/rst.23.2.1500","article-title":"Rift Valley fever","volume":"23","author":"Gerdes","year":"2004","journal-title":"Rev Sci Technol"},{"issue":"April (7)","key":"10.1016\/j.vaccine.2010.02.018_bib2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J Am Vet Med Assoc"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2010.02.018_bib3","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.1128\/JVI.78.18.9798-9806.2004","article-title":"NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription","volume":"78","author":"Billecocq","year":"2004","journal-title":"J Virol"},{"issue":"February (4)","key":"10.1016\/j.vaccine.2010.02.018_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0092-8674(04)00132-1","article-title":"TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus","volume":"116","author":"Le May","year":"2004","journal-title":"Cell"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2010.02.018_bib5","doi-asserted-by":"crossref","first-page":"e1000287","DOI":"10.1371\/journal.ppat.1000287","article-title":"Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation","volume":"5","author":"Ikegami","year":"2009","journal-title":"PLoS Pathog"},{"issue":"November (5)","key":"10.1016\/j.vaccine.2010.02.018_bib6","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am J Epidemiol"},{"issue":"August (1\u20132)","key":"10.1016\/j.vaccine.2010.02.018_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience","volume":"18","author":"Pittman","year":"1999","journal-title":"Vaccine"},{"issue":"February (1)","key":"10.1016\/j.vaccine.2010.02.018_bib8","first-page":"1","article-title":"Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine","volume":"30","author":"Smithburn","year":"1949","journal-title":"Br J Exp Pathol"},{"issue":"November","key":"10.1016\/j.vaccine.2010.02.018_bib9","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","article-title":"The development of a formalin-killed Rift Valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962","journal-title":"J Immunol"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2010.02.018_bib10","first-page":"155","article-title":"Rift Valley fever vaccine\u2014antibody and immune response in cattle to a live and an inactivated vaccine","volume":"50","author":"Barnard","year":"1979","journal-title":"J S Afr Vet Assoc"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2010.02.018_bib11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2460\/ajvr.1980.41.10.1559","article-title":"Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep","volume":"41","author":"Harrington","year":"1980","journal-title":"Am J Vet Res"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2010.02.018_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jmv.20624","article-title":"Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine","volume":"78","author":"Botros","year":"2006","journal-title":"J Med Virol"},{"issue":"May (3)","key":"10.1016\/j.vaccine.2010.02.018_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.4269\/ajtmh.1986.35.660","article-title":"Experimental infection and protection of lambs with a minute plaque variant of Rift Valley fever virus","volume":"35","author":"Moussa","year":"1986","journal-title":"Am J Trop Med Hyg"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2010.02.018_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever","volume":"52","author":"Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.02.018_bib15","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"issue":"November (49\u201350)","key":"10.1016\/j.vaccine.2010.02.018_bib16","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"issue":"March (2)","key":"10.1016\/j.vaccine.2010.02.018_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","article-title":"Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus","volume":"385","author":"Naslund","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.02.018_bib18","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","article-title":"Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus","volume":"24","author":"Spik","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.018_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1743-422X-6-6","article-title":"Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs","volume":"6","author":"Lagerqvist","year":"2009","journal-title":"Virol J"},{"issue":"February (3)","key":"10.1016\/j.vaccine.2010.02.018_bib20","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"Bouloy","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2010.02.018_bib21","doi-asserted-by":"crossref","first-page":"e5171","DOI":"10.1371\/journal.pone.0005171","article-title":"Establishment of a bluetongue virus infection model in mice that are deficient in the Alpha\/Beta interferon receptor","volume":"4","author":"Calvo-Pinilla","year":"2009","journal-title":"PLoS ONE"},{"issue":"October (Pt 10)","key":"10.1016\/j.vaccine.2010.02.018_bib22","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"issue":"June (5167)","key":"10.1016\/j.vaccine.2010.02.018_bib23","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"Muller","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2010.02.018_bib24","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1016\/j.vaccine.2008.07.042","article-title":"Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep","volume":"26","author":"Lorenzo","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.018_bib25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1743-422X-5-82","article-title":"Rift Valley fever virus structural proteins: expression, characterization and assembly of recombinant proteins","volume":"5","author":"Liu","year":"2008","journal-title":"Virol J"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2010.02.018_bib26","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20050821","article-title":"Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection","volume":"202","author":"Kolumam","year":"2005","journal-title":"J Exp Med"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2010.02.018_bib27","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.4049\/jimmunol.176.6.3315","article-title":"Cutting Edge: The direct action of type I IFN on CD4 T cells is critical for sustaining clonal expansion in response to a viral but not a bacterial infection","volume":"176","author":"Havenar-Daughton","year":"2006","journal-title":"J Immunol"},{"issue":"January (2)","key":"10.1016\/j.vaccine.2010.02.018_bib28","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2006.08.002","article-title":"Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins","volume":"357","author":"Gerrard","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.02.018_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.virol.2008.02.006","article-title":"Immunization with Toscana virus N-Gc proteins protects mice against virus challenge","volume":"375","author":"Savellini","year":"2008","journal-title":"Virology"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10001866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10001866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T22:06:58Z","timestamp":1739916418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10001866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":29,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0264410X10001866"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.02.018","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}